----
Current ValuationThe current P/E ratio is -33.99, within the reasonable range, cheaper than 76.85% of the time in the past 3 years, and the industry ranks 13/14, the industry Median -0.13.
-33.99xP/E
$1.15Stock price
$-0.03Earnings per share
-33.99xP/E
Stock price$1.15Earnings per share$-0.03
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- -13.99x
- Typical range
- -38.83x–-5.74x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
08162432
The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x10x20x30x40x50x
| Name/Symbol | |||
|---|---|---|---|
AHCOUSAdaptHealth | -3.35x | 145.14% | $763.53M |
AHGUSAkso Health | -33.99x | -- | $634.64M |
ACHUSAccendra Health | -0.13x | 89.03% | $38.85M |
COSMUSCosmos Health | -1.57x | 66.67% | $38.24M |
ZSTKUSZeroStack | -0.07x | 90.76% | $11.81M |
MEDSUSDataMeds AI | -0.13x | -- | $11.27M |
POMUSPomdoctor | -0.12x | -- | $6.41M |
ATPCUSAgape ATP | -1.82x | -- | $2.06M |
VRAXUSVirax Biolabs | -0.35x | 52.53% | $1.75M |
BIMIUSBIMI International Medical | -- | -- | $1.40K |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
